Safety, Tolerability and Blood Sampling of GSK3923868 Administered Via Dry Powder Inhaler to Healthy Participants of Chinese, Japanese and European Ancestry

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 2, 2024

Primary Completion Date

November 1, 2024

Study Completion Date

November 1, 2024

Conditions

Respiratory Tract Infections

Interventions

DRUG

GSK3923868

Participants will receive single dose of GSK3923868.

DRUG

Placebo

Participants will receive single dose of Placebo.

Trial Locations (1)

GSK Investigational Site, Middlesex